About: Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil
Creator	Borja-Cabrera, G Palatnik-De-Sousa, C Santos, F Batista, L Bauer, F Menz, I Morgado, A Parra, L Soares, I
Source	Elsevier; Medline; PMC
abstract	Abstract Leishmune® is the industrialized version of the FML-saponin vaccine which has been shown to develop 92–95% protection in vaccinated dogs and 76–80% vaccine efficacy against field canine visceral leishmaniasis (CVL) in Brazil. Leishmune® has been proven to be safe and tolerable and a transmission-blocking vaccine which renders vaccinated dogs non-infectious to sand fly vectors. In the present investigation, 550 healthy seronegative dogs of endemic and epidemic areas of Brazil were monitored for Leishmune®-induced immunogenicity during a 2-year trial. Another group of 588 untreated exposed dogs was also studied in parallel. Both groups were seronegative on day 0. The strong immunogenicity induced by Leishmune® vaccine was demonstrated by the 98% of FML-seroconversion, increase in absorbencies, the 82.7% DTH positive reactions and increase in skin test size diameters, the average increase in CD8+ total lymphocytes population in blood (27.1%), expected for QS21 saponin-containing vaccine, the sustained proportions of CD4+ T cells, and the average increased proportions of CD21+ B lymphocytes (42.3%). The Leishmune®-induced protection against CVL is demonstrated by the results: 98.8% asymptomatic dogs (at the end of first year) and 99% healthy survivors (at the end of the second year) among vaccinated dogs, compared to the 79.4% asymptomatic and 61% survivor dogs (p <0.001) monitored in the untreated exposed cohort. In spite of the low vaccine coverage, it was possible to detect a 66.1% (p <0.005) reduction in Belo Horizonte and an 80.2% (p <0.005) reduction in Araçatuba of the incidence of CVL among vaccinated dogs, when compared to the global incidence of CVL of each town, respectively. Our preliminary results support the potential use of Leishmune® to prevent CVL epidemics.
has issue date	2008-09-15(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2008.07.029
bibo:pmid	18675868
has license	els-covid
sha1sum (hex)	0e12e3191e6ce998f711be57eba12fe211dd3f72
schema:url	https://doi.org/10.1016/j.vaccine.2008.07.029
resource representing a document's title	Immunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil
has PubMed Central identifier	PMC7173152
has PubMed identifier	18675868
schema:publication	Vaccine
resource representing a document's body	covid:0e12e3191e6ce998f711be57eba12fe211dd3f72#body_text
is schema:about of	named entity 'demonstrated' named entity 'induced' named entity 'diameters' named entity 'induced' named entity 'CVL' named entity 'vaccinated' named entity 'DTH' named entity 'size' named entity 'VACCINE EFFICACY' named entity 'SUSTAINED' named entity 'PARALLEL' named entity 'INCIDENCE' named entity 'SAND FLY' named entity 'PROTECTION' named entity 'GROUP' named entity 'MONITORED' named entity 'seronegative' named entity 'cohort' named entity 'epidemic' named entity 'global' named entity 'compared' named entity 'monitored' named entity 'seronegative' named entity 'efficacy' named entity 'dogs' named entity 'vaccine' named entity 'survivor' named entity 'vaccine' named entity 'lymphocytes' named entity 'prevent' named entity 'investigation' named entity 'Brazil' named entity 'potential' named entity 'Belo Horizonte' named entity 'dogs' named entity 'epidemic' named entity 'visceral leishmaniasis' named entity 'seronegative' named entity 'sand fly' named entity 'non-infectious' named entity 'endemic' named entity 'immunogenicity' named entity 'lymphocytes' named entity 'assay' named entity 'Immunogenicity' named entity 'dogs' named entity 'CD4+ cells' named entity 'antigen' named entity 'morbidity' named entity 'Phase III' named entity 'antigens' named entity 'Rio de Janeiro' named entity 'Araç' named entity 'parasite' named entity 'protein' named entity 'CD21' named entity 'saponin' named entity 'immunotherapeutic' named entity 'NaCl' named entity 'lyophilized' named entity 'subcutaneous' named entity 'immunogenic' named entity 'veterinarians' named entity 'seropositive' named entity 'skin lesions' named entity 'vaccine' named entity 'CD4+' named entity 'vaccine' named entity 'parasites' named entity 'immunophenotype' named entity 'epidemics' named entity 'Belo Horizonte' named entity 'vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software